Evidence map›Paper›PMID 39585785›Full record

ArticleeLife2024

Cancers adapt to their mutational load by buffering protein misfolding stress.

Susanne Tilk, Judith Frydman, Christina Curtis, Dmitri A Petrov

Registry-linked trialAbstract read
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07715903 (Phase I Study Evaluating Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07715903 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Phase I Study Evaluating Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2026 to 2031Enrolled20ConditionsColorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical CarcinomaArmsCarfilzomib
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Susanne TilkDepartment of Biology, Stanford University, Stanford, United States.ORCID https://orcid.org/0000-0002-9156-9360
Judith FrydmanDepartment of Biology, Stanford University, Stanford, United States.ORCID https://orcid.org/0000-0003-2302-6943
Christina CurtisDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, United States.ORCID https://orcid.org/0000-0003-0166-3802
Dmitri A PetrovDepartment of Biology, Stanford University, Stanford, United States.ORCID https://orcid.org/0000-0002-3664-9130

Funding

INSTITUTIONAL TRAINING GRANT IN GENOME SCIENCET32HG000044 · NHGRI · STANFORD UNIVERSITY · PI MICHAEL P. SNYDER · 1995 to 2026
$32.2M
Genomics of rapid adaptation in the lab and in the wildR35GM118165 · NIGMS · STANFORD UNIVERSITY · PI Dmitri Petrov · 2016 to 2026
$8.3M
Mechanism of the Eukaryotic Chaperonin TRiC/CCTR01GM074074 · NIGMS · STANFORD UNIVERSITY · PI FRYDMAN, JUDITH · 2005 to 2024
$6.8M
Forecasting tumor evolution: can the past reveal the future?DP1CA238296 · NCI · STANFORD UNIVERSITY · PI CURTIS, CHRISTINA N · 2018 to 2022
$5.5M
PROTEIN FOLDING IN THE EUKARYOTIC CYTOSOLR01GM056433 · NIGMS · STANFORD UNIVERSITY · PI Judith Frydman · 1997 to 2026
$5.0M
Organoid-based Discovery of Oncogenic Drivers and Treatment Resistance MechanismsU01CA217851 · NCI · STANFORD UNIVERSITY · PI CURTIS, CHRISTINA N, JI, HANLEE P · 2017 to 2021
$4.7M
NCI NIH HHS DP1 CA238296NCI NIH HHS U01 CA217851NCI NIH HHS U01CA217851NHGRI NIH HHS T32 HG000044NIGMS NIH HHS R01 GM056433NIGMS NIH HHS R01 GM074074NIGMS NIH HHS R35 GM118165NIH HHS DP1CA238296NIH HHS GM74074NIH HHS R35GM118165NIH HHS T32-HG000044-21
6 · The paper itself

Abstract

In asexual populations that don't undergo recombination, such as cancer, deleterious mutations are expected to accrue readily due to genome-wide linkage between mutations. Despite this mutational load of often thousands of deleterious mutations, many tumors thrive. How tumors survive the damaging consequences of this mutational load is not well understood. Here, we investigate the functional consequences of mutational load in 10,295 human tumors by quantifying their phenotypic response through changes in gene expression. Using a generalized linear mixed model (GLMM), we find that high mutational load tumors up-regulate proteostasis machinery related to the mitigation and prevention of protein misfolding. We replicate these expression responses in cancer cell lines and show that the viability in high mutational load cancer cells is strongly dependent on complexes that degrade and refold proteins. This indicates that the upregulation of proteostasis machinery is causally important for high mutational burden tumors and uncovers new therapeutic vulnerabilities.

Indexed as

MutationNeoplasmsProtein FoldingCell Line, TumorGene Expression Regulation, NeoplasticHumansProteostasiscancercancer biologyevolutionary biologyhumanmutational loadproteostasissomatic evolution

Identifiers

PMID39585785
PMCPMC11588338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.